Answers are grounded in this paper and cite their sources.
Observational analysis finds significant differences in benzodiazepine and antipsychotic doses for agitation, suggesting varied symptom control by formulation.
The significant difference in the number of PRN benzodiazepine and/or antipsychotic doses administered for agitation among the different formulations of VPA may suggest differences in symptom control. Further investigation is warranted.
No takes yet. Share an insight, caveat, or question.
Ley et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: